ProPhase Labs (PRPH) Outlines Major Milestones in Cancer Diagnostics, Genomics and COVID‑19 Receivables Recovery

ProPhase Labs, Inc. (PRPH) recently hosted an investor webinar where CEO Ted Karkus shared a detailed update on the company’s progress across diagnostics, genomics, and financial recovery efforts. Key highlights: ProPhase is advancing the commercialization of its BE-Smart Esophageal Cancer Test — a diagnostic aimed at early detection of esophageal cancer, targeting a market estimated at $7–14 billion. The company’s genomics arm, Nebula Genomics, continues to expand, offering Whole Genome Sequencing and building one of the world’s largest and most diverse DNA datasets. On the financial front, ProPhase is working through a strategic initiative with Crown Medical Collections to recover more than $50 million in COVID-19 related receivables — a move aimed at strengthening liquidity and balance‑sheet stability. Management emphasized a streamlined cost structure, diversification across business lines (diagnostics, genomics, consumer health), and near‑term catalysts that could unlock shareholder value. Looking ahead, ProPhase plans to scale up its DNA Complete® and DNA Expand™ product lines, accelerate the rollout of BE‑Smart™, and leverage its combined biotech, genomics, and consumer health capabilities to drive long‑term growth. #ProPhaseLabs #Genomics #CancerDiagnostics #BiotechNews #SlimScan #GrowthStocks #CANSLIM